LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

2,868

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

December 31, 2027

Study Completion Date

July 1, 2028

Conditions
SarcomaSoft Tissue SarcomaBone SarcomaBone MetastasesVenous ThromboembolismHematomaAnticoagulant-induced Bleeding
Interventions
DRUG

Aspirin 325mg

Aspirin 325 mg by mouth once daily

DRUG

Enoxaparin 40Mg/0.4mL Prefilled Syringe

Enoxaparin 40 mg subcutaneous injection once daily

Trial Locations (10)

21287

Johns Hopkins University, Baltimore

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic, Cleveland

65201

University of Missouri-Columbia Cancer Care, Columbia

70112

Louisiana State University Health, New Orleans

90404

University of California Los Angeles Health, Los Angeles

02114

Santiago Lozano-Calderon, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

08103

Cooper University Health Care, Camden

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

University of Missouri-Columbia

OTHER

lead

Massachusetts General Hospital

OTHER